Evidence map›Paper›PMID 42733848›Full record

ArticleiScience2026

Development of a lethal adult mouse model of Coxsackievirus B1 infection for antiviral research.

Changjian Fang, Kang Yu, Jia Xue, Wenkun Fu, Nanyi Liu, Chuanlai Yang, Wensong Su, Shiying Xu, Jiaoling Zhang, Aping Lin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Changjian FangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Kang YuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Jia XueState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Wenkun FuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Nanyi LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Chuanlai YangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Wensong SuDepartment of Critical Care Medicine, Zhongshan Hospital, Xiamen University, Xiamen 361004, P.R. China.
Shiying XuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Jiaoling ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Aping LinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Dequan PanState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Linghui ZhanDepartment of Critical Care Medicine, Zhongshan Hospital, Xiamen University, Xiamen 361004, P.R. China.
Wei WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.
Tong ChengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coxsackievirus B1 (CVB1), a clinically significant human enterovirus, causes a wide spectrum of diseases ranging from mild illness to severe, life-threatening conditions in susceptible individuals. However, investigations into CVB1 infection pathogenesis, as well as the development and evaluation of antiviral strategies, have long been constrained by the lack of immunocompetent animal models that recapitulate human CVB1 infections. In this study, we established a lethal CVB1 infection model in immunocompetent adult BALB/c mice. Using a reverse genetics approach, we generated the CVB1-XM0108 virus from a clinical isolate and infected adult BALB/c mice. Our results demonstrated that this virus exhibited a strong tropism for the pancreas, liver, and skeletal muscles, leading to extensive inflammation in these organs. Passive immunization with anti-CVB1 serum dose-dependently reduced viral replication, tissue damage, weight loss, and mortality. This pathologically relevant mouse model provides a valuable platform for advancing CVB1 therapeutic and vaccine development.

Indexed as

acute pancreatitisantiviral evaluationCoxsackievirus B1enterovirushepatitisinfectious cDNA clonemurine modelmyositis

Identifiers

PMID42733848
PMCPMC13571662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.